{"title":"her2低和her2零状态对三阴性乳腺癌病理完全缓解和生存的影响：一项荟萃分析","authors":"Yu Qin, Chenchen Pu, Yuping Fan, Kepeng Zhu","doi":"10.3389/fonc.2025.1631125","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To delve into the influence of different status of human epidermal growth factor receptor 2 (HER2) on the long-term survival of patients suffering from triple-negative breast cancer (TNBC), as well as the pathological complete response (pCR) following neoadjuvant therapy (NAT) via meta-analysis.</p><p><strong>Methods: </strong>A computer search in the Embase, PubMed, Web of Science, and Cochrane Library databases was executed up to January 13, 2025, to collect studies related to HER2 status in TNBC patients. The articles were screened per the inclusion and exclusion criteria. The required data were extracted. The study quality was appraised by means of the Newcastle-Ottawa Scale, and statistical analysis was carried out utilizing Stata 15.0 software.</p><p><strong>Results: </strong>36 studies involving 54,277 patients with TNBC were included. According to the meta-analysis, the pCR rate after NAT was more notable in the HER2-zero group compared to the HER2-low group (<i>RR</i> = 0.90, 95%<i>CI</i>: 0.86-0.93, <i>P <</i> 0.001). Regarding overall survival (OS), HER2-low patients exhibited a better prognosis (<i>HR</i> = 0.93, 95%<i>CI</i>: 0.90-0.97, <i>P</i> < 0.001). For disease-free survival, breast cancer-specific survival, and recurrence-free survival, HER2-low patients might experience an enhanced prognosis. However, the results did not exhibit statistically significant. The sensitivity analysis confirmed the robustness of the meta-analysis results. No publication bias existed in studies on each outcome indicator.</p><p><strong>Conclusion: </strong>HER2 status is essential for the prognostic assessment of TNBC patients, particularly in predicting pCR and OS outcomes.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier PROSPERO CRD-420250642369.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1631125"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460144/pdf/","citationCount":"0","resultStr":"{\"title\":\"Influence of HER2-low and HER2-zero status on pathologic complete response and survival in triple-negative breast cancer: a meta-analysis.\",\"authors\":\"Yu Qin, Chenchen Pu, Yuping Fan, Kepeng Zhu\",\"doi\":\"10.3389/fonc.2025.1631125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To delve into the influence of different status of human epidermal growth factor receptor 2 (HER2) on the long-term survival of patients suffering from triple-negative breast cancer (TNBC), as well as the pathological complete response (pCR) following neoadjuvant therapy (NAT) via meta-analysis.</p><p><strong>Methods: </strong>A computer search in the Embase, PubMed, Web of Science, and Cochrane Library databases was executed up to January 13, 2025, to collect studies related to HER2 status in TNBC patients. The articles were screened per the inclusion and exclusion criteria. The required data were extracted. The study quality was appraised by means of the Newcastle-Ottawa Scale, and statistical analysis was carried out utilizing Stata 15.0 software.</p><p><strong>Results: </strong>36 studies involving 54,277 patients with TNBC were included. According to the meta-analysis, the pCR rate after NAT was more notable in the HER2-zero group compared to the HER2-low group (<i>RR</i> = 0.90, 95%<i>CI</i>: 0.86-0.93, <i>P <</i> 0.001). Regarding overall survival (OS), HER2-low patients exhibited a better prognosis (<i>HR</i> = 0.93, 95%<i>CI</i>: 0.90-0.97, <i>P</i> < 0.001). For disease-free survival, breast cancer-specific survival, and recurrence-free survival, HER2-low patients might experience an enhanced prognosis. However, the results did not exhibit statistically significant. The sensitivity analysis confirmed the robustness of the meta-analysis results. No publication bias existed in studies on each outcome indicator.</p><p><strong>Conclusion: </strong>HER2 status is essential for the prognostic assessment of TNBC patients, particularly in predicting pCR and OS outcomes.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier PROSPERO CRD-420250642369.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1631125\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460144/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1631125\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1631125","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：通过meta分析，探讨人表皮生长因子受体2 （HER2）不同状态对三阴性乳腺癌（TNBC）患者长期生存的影响，以及新辅助治疗（NAT）后病理完全缓解（pCR）的影响。方法：在Embase、PubMed、Web of Science和Cochrane Library数据库中进行计算机检索，直到2025年1月13日，收集与TNBC患者HER2状态相关的研究。根据纳入和排除标准对文章进行筛选。提取了所需的数据。采用Newcastle-Ottawa量表评价研究质量，采用Stata 15.0软件进行统计分析。结果：共纳入36项研究，涉及54277例TNBC患者。meta分析显示，her2 -0组NAT后pCR率显著高于her2 -低组（RR = 0.90, 95%CI: 0.86 ~ 0.93, P 0.001）。在总生存期（OS）方面，HER2-low患者预后较好（HR = 0.93, 95%CI: 0.90-0.97, P < 0.001）。对于无病生存期、乳腺癌特异性生存期和无复发生存期，her2低的患者可能会有更好的预后。然而，结果没有统计学意义。敏感性分析证实了meta分析结果的稳健性。各结局指标的研究均不存在发表偏倚。结论：HER2状态对TNBC患者的预后评估至关重要，特别是在预测pCR和OS结果方面。系统评价注册：https://www.crd.york.ac.uk/prospero/，标识符PROSPERO CRD-420250642369。
Influence of HER2-low and HER2-zero status on pathologic complete response and survival in triple-negative breast cancer: a meta-analysis.
Objective: To delve into the influence of different status of human epidermal growth factor receptor 2 (HER2) on the long-term survival of patients suffering from triple-negative breast cancer (TNBC), as well as the pathological complete response (pCR) following neoadjuvant therapy (NAT) via meta-analysis.
Methods: A computer search in the Embase, PubMed, Web of Science, and Cochrane Library databases was executed up to January 13, 2025, to collect studies related to HER2 status in TNBC patients. The articles were screened per the inclusion and exclusion criteria. The required data were extracted. The study quality was appraised by means of the Newcastle-Ottawa Scale, and statistical analysis was carried out utilizing Stata 15.0 software.
Results: 36 studies involving 54,277 patients with TNBC were included. According to the meta-analysis, the pCR rate after NAT was more notable in the HER2-zero group compared to the HER2-low group (RR = 0.90, 95%CI: 0.86-0.93, P < 0.001). Regarding overall survival (OS), HER2-low patients exhibited a better prognosis (HR = 0.93, 95%CI: 0.90-0.97, P < 0.001). For disease-free survival, breast cancer-specific survival, and recurrence-free survival, HER2-low patients might experience an enhanced prognosis. However, the results did not exhibit statistically significant. The sensitivity analysis confirmed the robustness of the meta-analysis results. No publication bias existed in studies on each outcome indicator.
Conclusion: HER2 status is essential for the prognostic assessment of TNBC patients, particularly in predicting pCR and OS outcomes.
期刊介绍：
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
